[
{"title": "Former Warner Chilcott exec's kickbacks trial on tap for May", "overWrittenTitle": null, "altHeadline": "Former Warner Chilcott exec's kickbacks trial on tap for May", "uuid": "a50e26e3-9e2a-4dfb-8335-53e844b79313", "uri": "https://www.fiercepharma.com/pharma/former-warner-chilcott-exec-s-kickbacks-trial-on-tap-for-may", "type": "article", "primaryTaxonomy": {"label": "Pharma", "url": "https://www.fiercepharma.com/pharma"}, "publishedDate": "2016-04-18T15:51:02Z", "defaultTZ": "America/New_York", "teaser": "A much-watched pharma kickbacks case goes to trial next month. W. Carl Reichel, a former Warner Chilcott president, faces charges of conspiring to pay kickbacks to doctors.", "authors": [{"label": "Tracy Staton", "title": "Tracy Staton", "firstName": "Tracy", "lastName": "Staton", "links": {"profile": "https://www.fiercepharma.com/author/tracy-staton"}}], "arcImage": {"id": "333981", "uuid": "7b4a7bfc-4822-4c9f-a700-a7cbb3d55218", "alt": "Justice statue with sword and scales", "title": "", "caption": "none", "url": "https://qtxasset.com/2016-04/lady-justice-677945_1280.jpg?VersionId=vQAnPcRlXz7oOmRls91_.htMOrGE70vv", "derivatives": []}, "heroVideo": null, "byline": null, "sponsoredLabel": "Sponsored", "hideTaxonomy": false},
{"title": "UPDATED: J&J's Invokana under scrutiny in EU for potential link to toe amputations", "overWrittenTitle": null, "altHeadline": "J&J's Invokana under review in EU for possible link to toe amputations", "uuid": "cab635b2-9928-4c1d-9b1d-29f40fdbd017", "uri": "https://www.fiercepharma.com/pharma/updated-j-j-s-invokana-under-scrutiny-eu-for-potential-link-to-toe-amputations", "type": "article", "primaryTaxonomy": {"label": "Pharma", "url": "https://www.fiercepharma.com/pharma"}, "publishedDate": "2016-04-18T13:07:04Z", "defaultTZ": "America/New_York", "teaser": "J&J's hot-selling diabetes drug Invokana has already caught attention in the U.S. for safety issues, and now, it's facing a new review in Europe for a potential link to toe amputations.", "authors": [{"label": "Emily Wasserman", "title": "Emily Wasserman", "firstName": "Emily", "lastName": "Wasserman", "links": {"profile": "https://www.fiercepharma.com/author/emily-wasserman"}}], "arcImage": {"id": "333936", "uuid": "bda28244-ca5c-4b34-aa00-0d6928516737", "alt": "Invokana", "title": "", "caption": null, "url": "https://qtxasset.com/2016-04/invokana2.jpg?VersionId=KSai4QILv1NvHKPntNNDlPsID8xR79a.", "derivatives": []}, "heroVideo": null, "byline": null, "sponsoredLabel": "Sponsored", "hideTaxonomy": false},
{"title": "What's in a name? Plenty, if you're in the Merck vs. Merck trademark fight", "overWrittenTitle": null, "altHeadline": "Merck hits back at Merck in U.S. trademark fight", "uuid": "5b70801d-d140-4823-a600-c0106ce91e51", "uri": "https://www.fiercepharma.com/marketing/what-s-a-name-plenty-if-you-re-merck-vs-merck-trademark-fight", "type": "article", "primaryTaxonomy": {"label": "Marketing", "url": "https://www.fiercepharma.com/marketing"}, "publishedDate": "2016-04-18T12:45:20Z", "defaultTZ": "America/New_York", "teaser": "The Merck vs. Merck tug of war over trademark rights just heated up, as the German company hit back at its U.S.-based rival with its own allegations.", "authors": [{"label": "Tracy Staton", "title": "Tracy Staton", "firstName": "Tracy", "lastName": "Staton", "links": {"profile": "https://www.fiercepharma.com/author/tracy-staton"}}], "arcImage": {"id": "333876", "uuid": "a3fc6e61-7aff-4f5d-8700-eb644281ac12", "alt": "Merck KGaA new logo in front of building", "title": "", "caption": null, "url": "https://qtxasset.com/2016-04/058666.jpg?VersionId=KMjB50Xom.LysSMlwt1WaYBh_RghTNIA", "derivatives": []}, "heroVideo": null, "byline": null, "sponsoredLabel": "Sponsored", "hideTaxonomy": false},
{"title": "AstraZeneca eyes Xtandi windfall with potential \u00a37B bid for Medivation", "overWrittenTitle": null, "altHeadline": "AstraZeneca eyes Xtandi windfall with potential \u00a37B bid for Medivation", "uuid": "033932c7-0be4-4b83-a34e-78b183972391", "uri": "https://www.fiercepharma.com/pharma/astrazeneca-eyes-xtandi-windfall-potential-%C2%A37b-bid-for-medivation", "type": "article", "primaryTaxonomy": {"label": "Pharma", "url": "https://www.fiercepharma.com/pharma"}, "publishedDate": "2016-04-18T12:03:06Z", "defaultTZ": "America/New_York", "teaser": "Medivation reportedly turned down a recent bid from Sanofi--and now, it looks as if AstraZeneca may swoop in with its own \u00a37 billion bid for the biotech, which makes the prostate cancer pill Xtandi.", "authors": [{"label": "Carly Helfand", "title": "Carly Helfand", "firstName": "Carly", "lastName": "Helfand", "links": {"profile": "https://www.fiercepharma.com/author/carly-helfand"}}], "arcImage": {"id": "333976", "uuid": "be3a6ea3-998b-4b68-ac08-8a2e4871afe8", "alt": "Soriot", "title": "", "caption": null, "url": "https://qtxasset.com/2016-04/soriot2_0.jpg?VersionId=E72n7ykSewGPXuaYQ1Ded1kXYz88r2si", "derivatives": []}, "heroVideo": null, "byline": null, "sponsoredLabel": "Sponsored", "hideTaxonomy": false},
{"title": "Ogilvy CommonHealth primes cloud marketing platform with doctor data", "overWrittenTitle": null, "altHeadline": "Ogilvy CommonHealth primes marketing platform with doctor data", "uuid": "b0f50934-fc87-4837-9d06-6c0b72a643d7", "uri": "https://www.fiercepharma.com/marketing/ogilvy-commonhealth-primes-cloud-marketing-platform-doctor-data", "type": "article", "primaryTaxonomy": {"label": "Marketing", "url": "https://www.fiercepharma.com/marketing"}, "publishedDate": "2016-04-17T18:53:01Z", "defaultTZ": "America/New_York", "teaser": "Want to find and target specific types of doctors, individually?\u00a0Ogilvy CommonHealth Worldwide just launched a proprietary marketing cloud platform with 5.5 million detailed physician profiles.\r\n", "authors": [{"label": "Beth Snyder Bulik", "title": "Beth Snyder Bulik", "firstName": "Beth", "lastName": "Snyder", "links": {"profile": "https://www.fiercepharma.com/author/beth-snyder-bulik"}}], "arcImage": {"id": "333951", "uuid": "dfcd4f12-181b-42b8-b900-e80d562851b9", "alt": "Ogilvy", "title": "", "caption": null, "url": "https://qtxasset.com/2016-04/Ritesh_Patel.jpg?VersionId=2zXN43tCoJ42S0OmCm8k5j6c8gnsDeUi", "derivatives": []}, "heroVideo": null, "byline": null, "sponsoredLabel": "Sponsored", "hideTaxonomy": false},
{"title": "New York AG sues insurer over restrictive hep C coverage", "overWrittenTitle": null, "altHeadline": "New York AG sues insurer over restrictive hep C coverage", "uuid": "dc744370-7bf8-40ea-970c-121c181dd7ee", "uri": "https://www.fiercepharma.com/pharma/new-york-ag-sues-insurer-over-restrictive-hep-c-coverage", "type": "article", "primaryTaxonomy": {"label": "Pharma", "url": "https://www.fiercepharma.com/pharma"}, "publishedDate": "2016-04-15T12:39:36Z", "defaultTZ": "America/New_York", "teaser": "The New York State Attorney General has already taken some steps to find out why\u00a0insurers are limiting coverage of pricey hep C meds to the sickest patients but has stopped short of suing companies for their decisions. Now, he\u2019s stepping up his fight. New York Attorney General Eric Schneiderman\u2019s office is suing health insurer CDPHP for breaking the law by delaying coverage of hep C treatments until patients are in advanced stages of the disease, The Times Union reports. The said AG in a suit filed in a state Supreme Court that the Albany, NY-based insurer did not pay for medically necessary care and deceived members about their coverage.", "authors": [{"label": "Emily Wasserman", "title": "Emily Wasserman", "firstName": "Emily", "lastName": "Wasserman", "links": {"profile": "https://www.fiercepharma.com/author/emily-wasserman"}}], "arcImage": {"id": "333626", "uuid": "a4d30be3-ffad-411a-8403-0371ac094a38", "alt": "New York AG Eric Schneiderman", "title": "", "caption": "New York Attorney General Eric Schneiderman", "url": "https://qtxasset.com/2016-04/ericschneidermann.jpg?VersionId=c_NswXl_ttVeeTRSyhBbSWVnvoWeFE0G", "derivatives": []}, "heroVideo": null, "byline": null, "sponsoredLabel": "Sponsored", "hideTaxonomy": false},
{"title": "WuXi\u2019s Crelux acquisition to boost European expansion ", "overWrittenTitle": null, "altHeadline": "WuXi\u2019s Crelux acquisition to boost European expansion ", "uuid": "35e230f9-cd31-4dc0-a800-d74826057cd2", "uri": "https://www.fiercepharma.com/pharma-asia/wuxi-s-crelux-acquisition-to-boost-european-expansion", "type": "article", "primaryTaxonomy": {"label": "Pharma Asia", "url": "https://www.fiercepharma.com/pharma-asia"}, "publishedDate": "2016-04-15T11:25:26Z", "defaultTZ": "America/New_York", "teaser": "WuXi AppTec has bought Germany-based drug discovery provider Crelux as the Chinese company looks to move more deeply into Europe. ", "authors": [{"label": "Ben Adams", "title": "Ben Adams", "firstName": "Ben", "lastName": "Adams", "links": {"profile": "https://www.fiercepharma.com/author/ben-adams"}}], "arcImage": {"id": "333871", "uuid": "05cb7735-9335-4bd6-9502-2fd5efc306e6", "alt": "Crelux", "title": "", "caption": null, "url": "https://qtxasset.com/2016-04/CRELUX.jpg?VersionId=X6Jk.ThdbQOxVVFnTrNQCh_ST3Dnvljh", "derivatives": []}, "heroVideo": null, "byline": null, "sponsoredLabel": "Sponsored", "hideTaxonomy": false},
{"title": "Eisai gains Philippines approval for Aricept in new license ", "overWrittenTitle": null, "altHeadline": "Eisai gains Philippines approval for Aricept in new license ", "uuid": "8f4eb481-f90f-4316-8654-844d4d4b4af1", "uri": "https://www.fiercepharma.com/pharma-asia/eisai-gains-philippines-approval-for-aricept-new-license", "type": "article", "primaryTaxonomy": {"label": "Pharma Asia", "url": "https://www.fiercepharma.com/pharma-asia"}, "publishedDate": "2016-04-15T10:28:24Z", "defaultTZ": "America/New_York", "teaser": "Seventeen years after the Philippines first approved Eisai and Pfizer\u2019s Alzheimer\u2019s drug Aricept, the country has now granted a new license for patients with Lewy body dementia. ", "authors": [{"label": "Ben Adams", "title": "Ben Adams", "firstName": "Ben", "lastName": "Adams", "links": {"profile": "https://www.fiercepharma.com/author/ben-adams"}}], "arcImage": {"id": "333596", "uuid": "03ce0e02-e726-4307-b003-3f5ef253f38c", "alt": "Brain imaging", "title": "", "caption": null, "url": "https://qtxasset.com/2016-04/imaging.jpg?VersionId=lbj_wcvDc29YKlu5yoAoq.FCPVJmLdR3", "derivatives": []}, "heroVideo": null, "byline": null, "sponsoredLabel": "Sponsored", "hideTaxonomy": false},
{"title": "Pfizer delay, alleged price gouging earns wrath of British watchdog ", "overWrittenTitle": null, "altHeadline": "Pfizer delay, alleged price gouging earns wrath of British watchdog ", "uuid": "eb30ed1a-490d-4270-ac00-c02bdb67c42e", "uri": "https://www.fiercepharma.com/pharma/pfizer-delay-alleged-price-gouging-earns-wrath-of-british-watchdog", "type": "article", "primaryTaxonomy": {"label": "Pharma", "url": "https://www.fiercepharma.com/pharma"}, "publishedDate": "2016-04-15T07:56:36Z", "defaultTZ": "America/New_York", "teaser": "In case anyone thought it was just the U.S. where pharma is accused of hiking prices, the U.K. has been quick to remind everyone it happens across the pond, hitting Pfizer with a \u00a310,000 penalty.", "authors": [{"label": "Ben Adams", "title": "Ben Adams", "firstName": "Ben", "lastName": "Adams", "links": {"profile": "https://www.fiercepharma.com/author/ben-adams"}}], "arcImage": {"id": "333586", "uuid": "cf72a9bd-c4cd-4282-8800-cd59d5ae2eff", "alt": "Pfizer HQ", "title": "", "caption": null, "url": "https://qtxasset.com/2016-04/pfehq_1.jpg?VersionId=C62_8JfJMikmaSiNJ5eXoiUjNEMnw_NV", "derivatives": []}, "heroVideo": null, "byline": null, "sponsoredLabel": "Sponsored", "hideTaxonomy": false},
{"title": "Will new drug spending figures increase pressure on pharma?", "overWrittenTitle": null, "altHeadline": "Will new drug spending figures increase pressure on pharma?", "uuid": "3352d9a8-6a10-40d4-8104-4cbd05d8343d", "uri": "https://www.fiercepharma.com/pharma/will-new-drug-spending-figures-increase-pressure-on-pharma", "type": "article", "primaryTaxonomy": {"label": "Pharma", "url": "https://www.fiercepharma.com/pharma"}, "publishedDate": "2016-04-14T12:51:23Z", "defaultTZ": "America/New_York", "teaser": "The annual report on how much the U.S. pays for meds is out--and it will likely serve to further anger those who believe pharma is hiking its prices.", "authors": [{"label": "Ben Adams", "title": "Ben Adams", "firstName": "Ben", "lastName": "Adams", "links": {"profile": "https://www.fiercepharma.com/author/ben-adams"}}], "arcImage": {"id": "333511", "uuid": "2fcdf082-d476-48bd-805c-92657f1051d3", "alt": "IMS", "title": "", "caption": null, "url": "https://qtxasset.com/2016-04/IMSReport.png?VersionId=LC_.29v.1x8iLJqyZseVbz4GgBNiXtrA", "derivatives": []}, "heroVideo": null, "byline": null, "sponsoredLabel": "Sponsored", "hideTaxonomy": false}
]